Immunotherapy Effective Results with respect to Cervical Cancer Pseudoprogression Events

Release Date: 15-Nov-2020

Immune checkpoint inhibitors effectiveness was observed in the patients suffering from recurrent cervical cancer, including early, delayed, and serial events. The primary aim of the research conducted with respect to the testing of immune checkpoint inhibitors in case of cervical cancer was to study the pseudoprogression among enrolled patients. A total of 303 patients suffering from recurrent cervical cancer were recruited in the clinical research study. All the patients who were enrolled in the study received balstilimab which is an anti-PD-1 antibody alone or in combination with other immune checkpoint inhibitor drug i.e. zalifrelimab (antiandndash;CTLA-4 antibody) for pseudoprogression.

Pseudoprogression in the patients is the estimation of the disease progression which is followed by tumor shrinkage, stable disease. The events of pseudoprogression in the patients were observed in minimum 7% of the patients i.e. 21 patients out of 303 enrolled patients. The enrolled patients who received combination ICIs pseudoprogression was observed in 6% of the population and delayed events of pseudoprogression was observed in 3% of the enrolled patients. Also, 4%, andlt;1%, andlt;1% of the patients who received balstilimab alone experienced early development, delayed development and serial pseudoprogression respectively. It was concluded that all the pseudoprogression events that were observed were under clinical benefit and was found to be promising for taking the clinical research forward.